Coherus and AbbVie File Dueling Motions for Injunctive Relief Relating to Coherus's HUMIRA Biosimilar | Goodwin
Our readers may recall that nine HUMIRA biosimilars have been licensed to launch in July 2023, with Amgen’s AMJEVITA the only one to launch to date.
Source: jdsupra.com